COVIDAX is a historically unique opportunity to invest in a sector that is otherwise restricted to few big pharma corporations and large investment funds. COVID-19 destroyed millions of lifes and broke the world economy. We are one of the very few truly independent scientific teams with sufficient expertise and resources to develop our own COVID-19 vaccine. In the global race for a vaccine, this is unique. You can invest in us right from this website, starting from October 2020. Help us bring the vaccine to all people in need, independently of all the political and corporate pressure, and get a share of the future profit.
Let’s build a world where people take matters into their own hands
We are a private biotech company independent of big pharma or other entities. Building on 21 years of research in Alzheimer’s disease, initiated by Prof. Novak’s team after his discovery of key pathological changes of tau proteins at Laboratory of molecular biology, MRC, Cambridge, UK in 1988, we are now putting our proprietary technology to use to develop our own vaccine against COVID-19.
There is a global race for a vaccine. In comparison to other vaccine candidates, our solution is tailored to elderly population and people with immunodeficiencies, who are especially vulnerable to the COVID-19. Our vaccine is unique because it contains only functionally important pieces of the target viral protein, thus limiting negative side-effects after treatment and stimulating the immune system.
Using our previous technology platform, we can get to clinical trials and ultimately the vaccine approval much more effectively and in a much shorter time. We want to stay independent and open the project to people for investment. Support us now and be part of the first independent vaccine against COVID-19.
Discovery of tau proteins by Prof. Novak in a team of Nobel Prize laureates at MRC Cambridge.
Prof. Novak co-founded AXON Neuroscience to use his groundbreaking discovery in the research of Alzheimer‘s disease.
The first tau vaccine AADvac1entered into the clinical trials
Positive phase II results with the world's first Tau Vaccine for Alzheimer's Disease - AADvac1
First exploratory use of Axon’s vaccine platform to develop a vaccine against COVID-19.
April - September 2020
Patent and pre-clinical trials
Investors can begin investing in the project from this website.
Quarter 4 2020
First-in-human clinical trials (planned).
Send us an email or call and we will be happy to talk some more.